Immunodiagnosis of prostate cancer: an evaluation of cell-mediated immunity.
Leukocyte adherence inhibition (LAI), a suggested in vitro correlate of cell-mediated immunity, was employed to identify patients with various stages of adenocarcinoma of the prostate on the basis of their degree of reactivity to prostatic tumor-associated antigens. Eighty-one percent of the patients and 56% of the controls were identified correctly. The efficiency of LAI was based on the sensitivity and specificity of the test. Our data revealed the absence of any correlation between patients' clinical stage of the disease and their in vitro reactivity to prostatic tumor-associated antigens.